Mobidiag implementeert productielijn om te voldoen aan gestegen vraag naar Novodiag®-patronen
ESPOO, Finland–(BUSINESS WIRE)– Mobidiag Ltd., een Fins bedrijf voor moleculaire diagnostiek, heeft een overeenkomst gesloten met Ginolis, expert in de automatisering van assemblage en zeer accurate werkprocessen met vloeistof. Door de baanbrekende productielijnen van Ginolis in te voeren, is Mobidiag in staat te voldoen aan de stijgende vraag naar moleculaire diagnostiek voor routinetests. Het bedrijf bereidt hiermee de productie van testpatronen van het type Novodiag® voor.
Novodiag®, dat in december 2017 werd gelanceerd, analyseert onmiddellijk monsters van patiënten met behulp van een wegwerppatroon. Binnen een uur levert de test volledige resultaten op. Dit in tegenstelling tot gangbare methodes, die in het tijdsbestek van dagen resultaat opleveren. Novodiag® draagt bij aan snellere en accuratere besluitvorming rond medische behandelingen, wat onnodig antibioticagebruik tegengaat.
Mobidiag Implements High Throughput Manufacturing Lines to Answer Growing Needs for Novodiag® Cartridges
ESPOO, Finland–(BUSINESS WIRE)– Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company, today announced it has signed an agreement with Ginolis, expert in assembly automation and high precision liquid handling solutions. Through the implementation of cutting-edge production lines from Ginolis, Mobidiag will be able to answer growing needs in molecular diagnostics for routine use and anticipate the production of upcoming Novodiag® test cartridges.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180304005019/en/
Novodiag® disposable cartridge for diagnostics of infectious diseases (Photo: Mobidiag)
Launched in December 2017, the new Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour, compared to days with well-established culture methods. Novodiag® helps make treatment decisions faster and more accurate, avoiding for example the unnecessary use of antibiotics.
“The innovative Novodiag cartridge has been developed at Mobidiag thanks to the combination of multidisciplinary teams and expertise. The cartridge includes state-of-the-art technologies such as qPCR and microarray, bringing with them some specific requirements and constraints. We then needed to successfully automate our processes and move from a small scale production capacity to industrial volumes without compromising quality and costs. Thanks to its cutting-edge modular platforms and expertise in diagnostics processes, we are confident that Ginolis will bring the most relevant solution to support us in our growing activity”, says Tuomas Tenkanen, CEO at Mobidiag.
The manufacturing solution developed for Mobidiag is based on Ginolis’ modular Xanthia automation platform. Its compact and modular design allows for high quality automation within a small footprint, saving valuable space in the clean room environment. In addition to Ginolis’ patented dispensing technology, the line is equipped with laser welding, precision assembly, ultrasonic welding and line confocal imaging (LCI) for quality inspection.
“The demand for molecular diagnostics is on the rise and we are proud to continue our long-standing cooperation with Mobidiag. Both companies share a dedication to innovation and high quality”, says Ginolis CEO Teijo Fabritius. “This line is a testament to the scalability of our flexible modular solutions and ability to integrate the entire manufacturing process on one platform.”
Antibiotic resistance is one of the greatest threats to the world’s health. According to the World Health Organization, the number of antibiotic-resistant bacteria grows at an alarming rate worldwide and all efforts should be taken to stop this development. Fast and reliable diagnostics are needed to detect resistance and thereby reduce the use of antibiotics.
With rapid tests and high-capacity production lines, Mobidiag is able to respond to rapidly growing requirements for infection diagnosis, including antibiotic resistance. A Novodiag® cartridge currently under development and planned to be released in mid-2018.
About Novodiag®
The Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour.
Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is particularly suitable for low volumes and on demand testing for clinical laboratories.
Learn more about Novodiag®.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.
To learn more, visit www.mobidiag.com
About Ginolis Ltd.
Ginolis specializes in providing high-quality automation, liquid handling and quality control solutions for the production and processing of healthcare consumables. The company is privately owned and headquartered in Oulu, Finland, with sites in Uppsala, Sweden, San Diego, USA and Suzhou, China.
To learn more, visit Ginolis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180304005019/en/
Contacts
Mobidiag Ltd
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com
or
Ginolis
Teijo Fabritius, +358 40 565 1782
CEO
teijo.fabritius@ginolis.com